AllianceBernstein’s Zevra Therapeutics ZVRA Stock Holding History

AllianceBernstein’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$658K	Buy	70,590 +5,400	+8%	+$60K	﹤0.01%	2574
2026 Q1	$584K	Hold	65,190	–	–	﹤0.01%	2559
2025 Q4	$584K	Sell	65,190 -5,110	-7%	-$48.3K	﹤0.01%	2580
2025 Q3	$669K	Hold	70,300	–	–	﹤0.01%	2535
2025 Q2	$619K	Buy	70,300 +54,200	+337%	+$440K	﹤0.01%	2518
2025 Q1	$121K	Hold	16,100	–	–	﹤0.01%	3036
2024 Q4	$134K	Hold	16,100	–	–	﹤0.01%	3093
2024 Q3	$112K	Buy	16,100 +5,970	+59%	+$40.5K	﹤0.01%	3118
2024 Q2	$49.6K	Buy	+10,130	New	+$48K	﹤0.01%	3190
2022 Q2	–	Sell	-11,400	Closed	-$57K	–	3400
2022 Q1	$57K	Hold	11,400	–	–	﹤0.01%	3168
2021 Q4	$99K	Hold	11,400	–	–	﹤0.01%	3198
2021 Q3	$106K	Sell	11,400 -11,400	-50%	-$115K	﹤0.01%	3180
2021 Q2	$292K	Buy	+22,800	New	+$245K	﹤0.01%	3018

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AllianceBernstein's ZVRA Position: Q2 2026 in Review

AllianceBernstein increased its Zevra Therapeutics (ZVRA) stake by 8.3% in Q2 2026, buying an estimated $60K and bringing the position to 70,590 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #2574.

AllianceBernstein first reported a position in ZVRA in Q2 2021 and has held it in 13 quarters since. The position peaked at $669K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

AllianceBernstein held 70,590 shares of Zevra Therapeutics worth $658K as of Q2 2026.
AllianceBernstein bought 5,400 Zevra Therapeutics shares in Q2 2026, an estimated $60K.
Zevra Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2574 holding.
AllianceBernstein first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 13 quarters since.
AllianceBernstein's Zevra Therapeutics position peaked at $669K in Q3 2025.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.